Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Depression in Mild Cognitive Impairment
NCT06069843Phase 2Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD) and Mild Cognitive Impairment (MCI), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Patient Rated Inventory of Side Effects at 1 month. Started Nov 2024; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT06069843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06069843.